

17
~~25~~ (NEW). The method of claim 24 wherein said antagonist is administered in a dose of about 0.05 to about 25 mg/kg.

18
~~26~~ (NEW). The method of claim 24 wherein said antagonist is administered in combination with a pharmaceutically acceptable carrier.

19
~~27~~ (NEW). The method of claim 24 wherein said antagonist is an antibody immunoreactive with IL-12.

20
~~28~~ (NEW). The method of claim 24 wherein said antagonist is an antibody fragment reactive with IL-12.

REMARKS

The foregoing amendments are presented in the above-captioned application; consideration and allowance of new claims 24-28 as now presented, are requested.

Please note that this application is a divisional of 08/560,943, which is a file-wrapper-continuation of application 08/212,629. Therefore, the claims as initially filed in this divisional application have been presumed to be the same as those initially filed in the 08/560,943 file-wrapper-continuation application, which were claims 1-9 and 16-23, as amended, of the 08/212,629 original application. However, these initially filed claims have been canceled, and new claims 24-28 added. The claims as now presented are reproduced in Exhibit A attached hereto for the Examiner's convenience. A favorable action is solicited.

No fee is believed due in this regard. Should any fee be required, authorization is hereby given to charge deposit account no. 07-1060.